Abstract:Background:Non-small cell lung cancer (NSCLC) frequently metastasizes to bone, leading to poor prognosis. Siglec15 has been identified as a newly discovered immune checkpoint and exists in a variety of tumors. However, the expression and function of Siglec15 in NSCLC and bone metastasis remains largely unclear.Methods:Siglec15 expression in NSCLC and the correlation between Siglec15 expression and the clinicopathological factors of patients with NSCLC were analyzed using The Cancer Genome Atlas (TCGA) dataset. Correlation analysis between Siglec15 and bone metastasis-related genes expression was based on the Molecular Signatures Database (MSigDB). Western blotting and immunohistochemistry were applied to detect Siglec15 expression in NSCLC and spinal metastasis. Human A549 and mouse CMT167 cells were transfected with Siglec15 siRNA to investigate its biological functions in NSCLC proliferation, migration, and invasion. The immune-related signaling pathways and correlations between Siglec15 and tumor-infiltrating immune cells and different immune checkpoints in the NSCLC tumor microenvironment (TME) were analyzed using Estimating Relative Subsets of RNA Transcripts (CIBERSORT) and gene set enrichment analysis (GSEA). To demonstrate Siglec15 in NSCLC cell-mediated T cell suppression and investigate the potential mechanism of Siglec15 silencing in antitumor immunity, we used a T cell killing assay in vitro and the high‑throughput sequencing approach.Results:Siglec15 expression was positively associated with the tumor stage and lymph node metastasis, and was markedly up-regulated in NSCLC bone metastasis. Functionally, Siglec15 knockdown inhibited the proliferation, migration, and invasion of NSCLC cells (A549 and CMT167 cell lines). A total of eight kinds of tumor-infiltrating immune cells were found to have a strong association with the Siglec15 expression in NSCLC cases. The expression of previously discovered immune checkpoints was higher in the high Siglec15 expression NSCLC group. Furthermore, an in vitro T cell killing assay showed that the down-regulation of Siglec15 in tumor cells could enhance the antitumor immune responses of CD8+ T cells. High‑throughput sequencing revealed the potential molecular mechanisms underlying the Siglec15-mediated immunosuppression effect of tumor cells on immune cells.Conclusions:Siglec15 may be involved in the pathogenesis of spinal metastasis in NSCLC and provide a new potential therapeutic target for the treatment of NSCLC and bone metastasis.

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer

Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer

Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy

Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I Via PI3K/Akt Activation in Bladder Cancer

Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer

LncRNA CASC15 Functions As an Oncogene by Sponging Mir-130B-3p in Bladder Cancer.

Glycosylation of Siglec15 promotes immunoescape and tumor growth

CD276-dependent Efferocytosis by Tumor-Associated Macrophages Promotes Immune Evasion in Bladder Cancer

S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma

Siglec15 Facilitates the Progression of Non-Small Cell Lung Cancer and is Correlated with Spinal Metastasis.

Siglec15 is a Prognostic Indicator and a Potential Tumor-related Macrophage Regulator that is involved in the Suppressive Immunomicroenvironment in Gliomas

Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Significance of Siglec‐15 Expression in Colorectal Cancer: Association with Advanced Disease Stage and Fewer Tumor‐infiltrating Lymphocytes

Bladder Cancer Intrinsic LRFN2 Drives Anticancer Immunotherapy Resistance by Attenuating CD8+ T Cell Infiltration and Functional Transition

PD1hi CD200hi CD4+ exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial–mesenchymal transition in bladder cancer

Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy

Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1

Bioinformatic analysis reveals prognostic value and immunotherapy potential of Siglec-15 in laryngeal squamous cell carcinoma